Meeting
2018 ASCO Annual Meeting
VXM01 phase I study in patients with progressive glioblastoma: Final results.
Authors
Wolfgang Wick
Neurology Clinic, DKFZ, DKTK, Heidelberg, Germany
Wolfgang Wick , Antje Wick , Felix Sahm , Dennis Riehl , Andreas von Deimling , Martin Bendszus , Philipp Kickingereder , Philipp Beckhove , Friedrich Hubertus Schmitz-Winnenthal , Christine Jungk , Sébastien Wieckowski , Lilli Podola , Christel Herold-Mende , Andreas Unterberg , Michael Platten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02718443
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2017)
DOI
10.1200/JCO.2018.36.15_suppl.2017
Abstract #
2017
Poster Bd #
175
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.
First Author: Wolfgang Wick
Poster
2017 ASCO Annual Meeting
VXM01 phase I study in patients with resectable progression of a glioblastoma.
First Author: Wolfgang Wick
Poster
2022 ASCO Annual Meeting
A phase I clinical trial on intracranial administration of autologous myeloid dendritic cells (myDC) in combination with ipilimumab and nivolumab in patients with recurrent glioblastoma (rGB).
First Author: Julia Katharina Schwarze
Poster
2020 ASCO Virtual Scientific Program
Controlled IL-12 in combination with a PD-1 inhibitor subjects with recurrent glioblastoma.
First Author: E. Antonio Chiocca